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Hematopoietic stem cell transplantation (HSCT) is one of a range of therapeutic options available to patients suffering from various
diseases. HSCT procedure involves important ethical and legal aspects that can occur at every phase of the procedure: the clinical
choice of whether to perform the procedure, pretransplantation preparation regimens, donor selection, stem cell harvest procedure,
transplantation phase, and short-term and long-term follow-up care. In this discussion paper, we outline the ethical issue-facing
physicians involved in HSCT. Currently, HSCT is a widely accepted treatment for many life-threatening diseases. It thus
represents a real therapeutic hope for many patients. It does, however, carry a burden of possible morbidity and mortality.
Consequently, there are substantial information and communication issues involved in the consent process for HSCT. In the
final decision, the judgements of different parties, such as patients, family members, and healthcare professionals, intersect and
overlap and this is particularly true when the patient is a minor. Finally, HSCT is a very expensive procedure. The social and
economic concerns of HSCT are discussed within the actual contextual framework of the dramatic increase in healthcare costs
and inequalities in healthcare in relation to socioeconomic status, educational status, and ethnicity.
1. Introduction
Hematopoietic stem cell transplantation (HSCT), either
autologous or allogeneic, is one of a range of therapeutic
options available to patients who suffer from refractory or
relapsing neoplastic disease and nonneoplastic genetic
disorders, as well as from chronic bone marrow failure. In
fact, over the last few decades, considerable progress has been
made with regard to HSCT because of major discoveries in
basic science, improved diagnostic procedures, and newer
therapies. Many patients have already benefitted from this
form of treatment, and the encouraging results obtained are
well known [1, 2].
HSCT is a very complex medical procedure which has led
to the development of groups of specialized healthcare
professionals with similar scientific interests and common
professional standards. In turn, this has also led to the pro-
duction of specific guidelines (e.g., on fertility preservation
and donor algorithm selection) [3–6].
Guidelines are important not only for the management of
medical issues but also for the HSCT procedure because it
involves important ethical and legal aspects [7, 8]. Ethical
problems concerning transplantation can occur at every
phase of the procedure: the clinical choice of whether to
perform the procedure, pretransplantation preparation
regimens, donor selection, stem cell harvest procedure, the
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transplantation phase (including hospitalization during mar-
row aplasia), and short-term and long-term follow-up care.
Moreover, since HSCT is also clearly associated with a
substantial risk of life-threatening acute complications as
well as significant organ toxicity, the quality of life during
and after HSCT, compared to that associated with alternative
treatments, is a very important issue which should be care-
fully discussed and evaluated with the patients.
In this discussion paper, we will outline bioethical issue-
facing physicians involved in HSCT and the wider scientific
community, with a particular focus on the difficulties in
defining an adequate consent process.
2. A European Overview
The number of HSCT-treated patients has significantly risen
over the last two decades, with estimates of 45,000–50,000
procedures performed each year worldwide [9]. In a global
perspective, more than 14 million typed volunteer donors
or cord blood units from the many registries worldwide pro-
vide stem cells for patients without family donors [10, 11].
A recent retrospective study [12] on behalf of the
Worldwide Network for Blood and Marrow Transplantation
(WBMT) showed that 953,651 HSCTs were registered from
1516 transplant centres in 75 countries. No transplants were
performed in countries with fewer than 300,000 inhabitants,
a surface area of less than 700km2, or a gross national income
per person of US$1260 or lower. As expected, transplant rates
were higher in countrieswithmore resources,more transplant
teams, and unrelated donor infrastructures [12]. Countries
with major socioeconomic concerns have the lowest HSCT
performances: Latin America numbers are lower than those
in North America and in European regions but higher
than those in the Eastern Mediterranean and Asia Pacific
regions [13, 14].
In Europe, an increase in the annual absolute HSCT
numbers and transplant rates has been reported [15]. How-
ever, also in Europe, economic factors, for example, gross
national product per capita, healthcare expenditure per
capita, type of healthcare system, and income in general,
strongly condition the transplant rates for each country
[16, 17]. Passweg et al. [15] report that in some evolving
European countries (i.e., Eastern Europe), the increase in
HSCT is particularly noticeable.
The field of tissue and cell donation and banking is now
highly regulated in many countries. According to the World
Health Organization (WHO) Aide-Mémoire on the donation
and transplantation of tissues and cells, national health
authorities are responsible for ensuring that the donation,
banking, and human application of tissues and cells are
promoted, regulated, and monitored appropriately in the
interests of patient safety and public transparency. More
specifically, they are responsible for ensuring that (a) an
appropriate legislative/regulatory framework is in place; (b)
national/international practice standards have been defined;
(c) there is inspection/authorisation of screening, testing,
procurement, processing, storage and distribution, imports,
and exports; (d) there are programmes for vigilance and sur-
veillance of adverse outcomes; and (e) there is monitoring
and reporting of donation, processing, storage, distribution,
and import and export activities.
The need for the international standardization of cell and
tissue banking practices has been felt in Europe since 1978.
In that year, the Council of Europe adopted Resolution (78)
that assessed the harmonization of legislation relating to the
removal, grafting, and transplantation of human substances.
Over the following years, several EuropeanUnion (EU)Direc-
tives have stated the requirements which have been (or are in
the process of being) transposed into the national legislation
of theEUmember states. Issues related to the safety andquality
of HSCs are regulated by European Directives 2004/23/EC
[18], 2006/17/EC [19], and 2006/86/EC [20].
These directives are legally binding for member states. In
addition, the guide to the quality and safety of tissues and cells
for humanapplicationwas issued by theEuropeanCommittee
(PartialAgreement) onOrganTransplantation (CD-P-TO) in
2013 and is in its second edition. This guide contains the
instructions considered to be the “minimum standards” that
align with relevant EU Directives in the field and provides
assistance for those states outside the EU that are considering
adopting the EU requirements in their legislation.
Furthermore, international standards for HSCT have
been developed in Europe by the Joint Accreditation Com-
mittee of the International Society for Cellular Therapy
(ISCT) and EBMT (JACIE), the European equivalent of the
US Foundation for the Accreditation of Cellular Therapy
(FACT) [21].
The report on the first ten years showed that 200
European programmes have applied for JACIE accreditation,
which has been granted in more than 100 cases. The report
identified the status of the transplant programme regarding
JACIE accreditation as the major factor affecting the overall
survival of recipients of allogenic transplantation [22, 23].
Although over the years almost all of the inspected European
centres were found to be functioning at a high level of excel-
lence [24, 25], a challenging step forward relates to collabora-
tive projects to implement the adoption of JACIE standards
as reference for the regulatory accreditation process, as it
already occurs in some European countries [26].
3. Medical and Economic Issues
Recent progress in several areas of cancer therapy (e.g., the
successful treatment of some hematopoietic malignancies)
has been quite remarkable, with cure rates of up to 80–90%
for certain diseases and in selected patient groups [27]. How-
ever, recently, there has also been a dramatic increase in
healthcare costs, and both insurance programmes and
national health systems are facing growing demands on
resources [28]. Reasons for this phenomenon include the
following:
(a) The costs related to prolonged and recurrent
hospitalization
(b) The availability of multiple treatment options
(including HSCT) which are not mutually exclusive
and therefore can be used sequentially
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(c) The price of newmedications (e.g., specific inhibitors,
monoclonal antibodies, and recombinant molecules)
(d) The aging of the population in Western countries.
In fact, the total number of cancer diagnoses and cancer
survivors is increasing [29] and growing numbers of older
individuals are receiving anticancer therapy which is often
intensive. Only intensive chemotherapy followed by hemato-
poietic cell transplantation is generally considered potentially
curative in neoplastic diseases.
HSCT is a very expensive procedure; however, it has the
clear advantage of potentially eradicating the neoplastic
clones. Indeed, the field of HSCT has made major progress
in the treatment of many conditions and has also proved that
stem cell therapy and immunotherapy are effective against
malignancies. The success of HSCT is derived both from
the ability to treat patients with intensive chemoradiotherapy
and, in some diseases like leukaemia, from potent graft-
versus-leukaemia (GVL) effects mediated by donor immune
cells. Importantly, HSCT has been a curative therapy also
for several nonmalignant hematologic disorders.
Notably, progress over the years has been remarkable in
understanding histocompatibility, graft-versus-host disease
(GVHD), GVL effect, and immune reconstitution after trans-
plant. The development of unrelated donor registries and
increased utilization of cord blood and partially matched
related donor transplants have all ensured that there is a
donor for nearly everyone who needs a transplant. Moreover,
improved donor selection, patient-tailored conditioning
regimens, and better supportive care measures have helped
reduce morbidity and mortality.
On the other hand, significant obstacles are disease
relapse, infectious complications, and regimen-related toxic-
ities. It is important to note that comorbid conditions also
interfere with effective therapy. Furthermore, intensive
chemotherapy-based conditioning regimens in older individ-
uals may be associated with considerable morbidity and the
need for prolonged hospitalization and rehabilitation, thus
stressing the system and draining family resources. Although
transplantation following low-intensity conditioning is being
carried out in patients even in their 70s, these are mostly
highly selected patients, and the data generated in clinical tri-
als are difficult to extrapolate to the population at large [30].
To make things even more complicated, in some patients,
HSCT-related complications are superimposed onto preex-
isting chronic organ insufficiency, such as renal insufficiency
related to previous nephrotoxic treatment. Notably, almost
all patients entering the HSCT procedure show significant
immunosuppression, either because of cytostatic or immu-
nosuppressive pretreatment or as a result of their underlying
disease.
As the focus of many older individuals is on the quality of
life, it is important to emphasize that, for various advanced
malignancies, emerging data indicate that the quality of life
may be better and survival may be longer with nontransplant
procedures and/or with palliative care.
As an example, the management of chronic myeloid
leukaemia (CML) has dramatically changed over the past
few years [31]. HSCT was the standard of care for eligible
patients until the 1990s. Despite the fact that considerable
results were obtained in those patients, better knowledge of
the molecular basis of CML led, in the late 1990s, to the
development of tyrosine kinase inhibitors (TKIs) which
revolutionized the management of the disease. TKIs are a
tool for achieving long-term disease control with simple oral
therapy and are now the first-line treatment. The majority of
patients treated with TKIs achieve excellent responses with
sustained treatment, and some even continue to have excep-
tionally low-level disease after TKI withdrawal. Therefore,
only to those with an inadequate response to any of the
currently available TKIs, should HSCT be offered as the best
option for achieving long-term survival.
Finally, a reassessment of treatment decisions in some
patients is probably needed. Medical doctors involved in
HSCT teams probably need not “oversell,” and particularly
older patients may not have a full understanding of the
impact of the proposed therapy on their lives. Our conversa-
tions with these patients must include a discussion of alterna-
tives and supportive care and, even more importantly, must
address end-of-life issues sand expectations.
4. Social and Cultural Issues
There is some evidence of inequalities in healthcare in
relation to socioeconomic status, educational status, and eth-
nicity [32–34]. Moreover, migrants are often more disadvan-
taged than the indigenous population because they have
moved from a poor environment, have a lower educational
status, and may have little understanding of the language.
As most migrants come from places with poor healthcare
facilities, they may have underlying health problems that
have been inadequately addressed over the years [35]. Fur-
thermore, since migrants have attitudes to healthcare associ-
ated with their own culture, they may respond less well to
preventive care opportunities such as vaccination. In fact,
many populations have a distinct perception of acute illness
but have no understanding of subclinical/asymptomatic
chronic diseases. Without an understanding of how to
manage chronic problems, patients may think that medica-
tions should be discontinued as soon as symptoms are no
longer present, and this can be detrimental when long-term
care is needed (e.g., preventing GVHD). In addition, each
exacerbation of symptoms may be seen as a separate illness
rather than, for example, the long-term side effects of HSCT,
especially if there are several symptoms. It is also likely that
remission will be understood as a definitive cure, and this is
particularly important to avoid following HSCT, when the
diagnosis of early relapse can be of vital importance, as in
acute leukaemia cases.
Finally, migrants are occasionally unfamiliar with health-
care practices in their host country (such as appointments
and registration procedures) that are important for successful
clinical management in the long-term follow-up after HSCT.
Overall, racial and ethnic minorities are less likely to receive
even routine medical procedures and more complex trans-
plantation procedures. The relationship of immigrants with
their physicians is as important as for other patients.
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Communication is an important part of healthcare, and
immigrants’ difficulties with the language of the host country
may cause difficulties in medical investigation, lack of recog-
nition of mental illness, and poor compliance with therapeu-
tic recommendations [36].
Immigrants’ individual beliefs about health and illness
are culturally determined and may affect health, self-care
practices, the type of healthcare sought, and the degree of
compliance. Beliefs are essential for self-care practice and
care-seeking behaviour and must be considered when plan-
ning clinical care and when offering HSCT.
Modern approaches to healthcare give the patient an
active role and characterize the relationship between the phy-
sician and the patient as a partnership. Immigrants, on the
other hand, are mostly inclined to accept illness as part of
their fate (due to superstition), and they have difficulty
discussing their problems with a medical advisor in a manner
that would give them an active role in their health manage-
ment. More common in their culture, perhaps, is having a
doctor tell them what to do. Their fear of an inability to work
and its inevitable economic consequences for the welfare of
their families dominate their behaviour during consultation
and when advised to undergo a complex procedure like
HSCT which implies long periods of hospitalization.
Finally, the vast majority of doctors have recently been
facing the problem of patients taking complementary and
alternative medicines, which clearly play no role in HSCT.
This can hamper communication, especially in cross-
cultural encounters. Recent immigrants and refugees who
are unfamiliar with Western healthcare are far less likely
to share such information. They may feel Western doctors
will not understand or approve of their culturally based
remedies, and they fear being judged for their “foreign”
beliefs. They may not be aware that preventing adverse
drug interactions depends on discussing all the medicines
they take with their doctor.
5. Bioethical Issues
Organ donation and transplantation has become gradually
more and more critical in the field of medicine, and it is
therefore of vital interest to society and law. As medical
knowledge advances, with scientists and investigators discov-
ering numerous therapeutic measures, organ donation and
transplantation has become indispensable, since the progress
of modern medicine enables a growing variety of possible
transplantations.
However, in organ donation and transplantation, donors’
and recipients’ priorities may conflict and create ethical
problems. Primary emphasis has thus to be placed on the
balance between potential risks and benefits for both the
donor and the recipient and the maintenance of a therapeutic
dimension of the entire donation/transplantation process.
When we shift to a broader vision that also invests the social
dimension of the phenomenon, the gap between availability
and need becomes a central knot [37]. As with organs, the
demand for some transplantable tissues and cells far out-
weighs the available supply. Individual motivation and
choice is only one part of the donation picture; the central
role of organizations, organizational procedures, and profes-
sionals in facilitating donation should be highlighted.
In general terms, difficulties in donating organs may
include lack of knowledge and misperceptions about organ
donation, difficulty obtaining familial consent in organ dona-
tion from the deceased, and insufficient infrastructure. The
personal ethical values, beliefs, and religiosity of the potential
donors may intersect with structural and organizational
barriers to explain the lack of organ availability.
In this scenario, HSC donation presents concerns that are
common to other organ and tissue donations: cultural and
personal values potentially affecting the decision to become
an HSC’s donor [38–41] and mistrust either of the medical
system at large or in the equitable allocation of HSC donation
[38, 41–45]. Satisfaction with the decision to donate or, in
contrast, fear of donation and of potential health conse-
quences may be other conditioning factors in all living organ
and tissue donations [46–48].
HSC donation presents particularities in comparison
with other types of tissue or organ donation that can affect
the donation rate [49]. It can be said that HSCT can be
situated on the middle ground between blood donation
and living organ donation [49]. However, HSC donation
carries many more risks and inconveniences compared to
blood donation. It may require the use of drugs such as
the granulocyte colony-stimulating factor (GCSF) with
the aim of harvesting enough stem cells from peripheral
blood or minor surgery and anaesthesia in bone marrow
donation. On the other hand, undoubtedly, HSC donation
is less burdensome, both physically and psychologically,
compared to the donation of organs (e.g., kidney and
liver) among living subjects.
A peculiarity of HSCT, perhaps even more than for other
types of transplant, is that human leukocyte antigen (HLA)
matching is of paramount importance, and it is the major
donor-related factor in the success of HSCT [50–52]. Fur-
thermore, in HSC transplantation, repeated donations may
be necessary [53]. Consequently, there may be quite a long
time interval between the moment the potential donor
decides to donate and enrols in a register or centre and the
donation actually taking place [49, 54]. It has been reported
that the time between enrolment and actual donation is, on
average, eight years [49]. Thus, a problem peculiar to
unrelated HSC donation is the long gap between the first
motivation to join a donor registry and the final act of
donation, usually several years later.
Furthermore, younger age groups seem to correlate
positively with the intention of donating HSCs [55]. These
elements should be taken into account, since potential
donors may change their mind over the years and may refuse
donation when the time comes. In the same way, repeated
donation may be refused.
Finally, HSCT is a complex, high-cost procedure and
depends on a well-established institutional infrastructure
network [56].
In conclusion, similarities between HSC donation and
other types of living tissue and organ donation exist;
however, given the particularities of HSC donation, specific
strategies to increase donation can be undertaken.
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The creation and implementation of stem cell banks and
registries is an important step towards increasing HSC dona-
tion since these organisms may play a pivotal role in recruit-
ing, registering, and coordinating more potential donors.
HSC registries may serve as hubs, linking donors, recipients,
clinics, biobanks, and regulatory agencies [57–60] and are
thus a useful tool also in promoting a donation culture. Pro-
viding accurate information and knowledge about stem cell
donation remains a priority in increasing the number of
donations. Recent studies have demonstrated that also edu-
cational and communicative efforts towards the medical
community may be beneficial in the recruitment and reten-
tion of donor populations [61, 62]. The creation of a social
and cultural atmosphere favouring the diffusion of correct
and proper information regarding HSC donation is central
in encouraging people to make a donation. Furthermore,
the motivation enhancement strategies employed by major
societies and agencies are critical in increasing HSC dona-
tion. With particular reference to HSC donation and due to
the long time lapse between the decision and actual donation,
the standards of the World Marrow Donor Association
(WMDA) assess the donor’s right to withdraw even if this
might entail serious and even fatal consequences for the
recipient. At the same time, they reiterate the importance of
the potential donor’s full understanding of the serious and
potentially life-threatening consequences to the recipient if
the donor chooses to withdraw at any time, but particularly
once the recipient’s pretransplant conditioning has begun
[63, 64]. Finally, a more effective promotion of HSC dona-
tion, which has traditionally relied on interpersonal commu-
nication and the mass media, is of paramount importance in
ensuring the sustainability and continuity of donation activ-
ities. The debate surrounding advertising and solicitation is
still unresolved [65–67]. As for the living donation of other
organs and tissues, the use of media and other forms of
communication to advertise the need for organs or tissue
for oneself or for a related person can be considered a univer-
sal right. Undoubtedly, patients and their families have the
right to tell their own stories publicly through any informa-
tion channel, and personal stories by the family members
and friends of patients often result in increased media inter-
est and can be used to communicate the importance of
registration and donation to any patient that could need it.
On the other hand, the increase in highly publicized
appeals for organ and tissue donation for individual patients
may give rise to concerns. First of all, it may be counterpro-
ductive to the needs of many others requiring organ trans-
plantation, having a potential direct or indirect impact on
less-fortunate or less-connected families. Furthermore, both
the correctness of information and the emotional pressure
on potential donors have to be carefully taken into account.
In conclusion, given that there is a stringent need to
improve HSC donation, several strategies may be under-
taken to encourage people to donate. The creation and
implementation of banks and registries and the diffusion
of a social and cultural atmosphere of donation through
information campaigns are pivotal to motivate people to
donate. Other strategies, such as advertising and solicita-
tion, are still debated and may be ethically acceptable as
long as certain conditions, such as correct information to
potential donors, are maintained [49].
When dealing with the bioethical issues related to HSCT,
the issue of informed consent is a very central one. Adults
with decision-making capacity have a long-recognized and
legally protected right to make decisions about their bodies
and health. Consent is a basic ethical consideration, implying
that it is informed and that patients must be given adequate
and accurate information. HSCT is a “high-stakes” medical
treatment [68]; people who are undergoing HSCT should
thus be prepared to participate in decisions that involve
weighing benefits, harm, long-term risks, and uncertainty
linked to the treatment itself [69].
From a general point of view, patients are increasingly
involved in decision making related to the nature of medica-
tions that reflect deliberative, personal choices. The literature
is full of contributions on the subtleties of informed consent,
thus finally reinforcing the ethical, legal, and deontological
requirements of the patient’s informed consent before under-
taking any medical procedure [70, 71].
Informed consent gives the patient the power and the
right to choose to opt out of/in the treatment. However, a
number of troubling issues cluster around the patient’s
decision on HSCT [8] since, in the final decision, judgements
made by different parties, such as patients, family members,
and healthcare professionals, intersect and overlap.
The first step is to assess the medical indications for and
the clinical effectiveness of HSCT. Is it reasonably expected to
benefit the patient? Are there predictable side effects? Are
these tolerable in the light of the expected benefits? As HSCT
is a high-risk procedure [72], these points are critical in form-
ing the judgements of both the physician and the patient.
However, the perception of risks relating to a medical proce-
dure is complex even for physicians [73] and the magnitude
of risks is only one of the several factors that may influence
it. Other factors that may contribute to risk perception by a
patient include perceived fear, the potential severity of the
risk, and how familiar or unfamiliar the risk is. Some risks,
therefore, may be more unacceptable than others that are
more familiar and perceived to be more controllable for a
single patient [74]. For example, some patients may place
greater emphasis on the potential for cure of their disease
and less importance on possible treatment-related side effects
that may develop, while other patients may have opinions
which are exactly opposite [75]. It has been reported that
overestimating the benefit of transplant is evidenced by the
fact that patients rate the perceived success of a cure after
HSCT as being 78% higher than their physicians do [76].
Furthermore, once the medical indication for HSCT is
established on the basis of sound science, patient preferences
remain essential in the light of the recommended medical
treatment, since HSCT involves several different aspects
which include domains related to emotional, physical,
mental, social functioning, and quality of life, potentially
impacting compliance to HSCT treatment. Patients’ percep-
tions and expectations are substantial in the decision-
making process, since it has been shown that the experience
of HSCT may have a wide, long-lasting, profound impact
on recipients [77, 78]. Lee et al. explored the discrepancies
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between the patients and their physicians regarding HSCT
and found that, in this clinical setting, patients and their phy-
sicians had the most concordant expectations when the out-
come of HSCT was likely to be good, while patients with
more severe disease failed to recognize the higher risks asso-
ciated with their clinical condition [74]. For example, a clear
association between actual survival and the physician’s esti-
mates, but not the patient’s estimates, was observed in a total
of 123 patients and their attending physicians by Grulke et al.
[77]. Such a situation reveals the complexity of the decision
in the specific setting of HSCT as a dispute may occur when
the patient’s preferences are contrary to the recommenda-
tions of the physician. The physician, wishing to provide a
benefit to the patient, offers HSCT. When the patient refuses
the medical recommendations even if the proposed treat-
ment may be lifesaving, the situation demands a positive
response following the bioethical principle of autonomy
[79]. However, a full rendering of the meaning of autonomy
implies that the patient’s capacity for such a decision is not
compromised: the physician has provided all the facts about
the patient’s disease, prognosis, and therapeutic alternatives,
and the patient has assessed each alternative treatment in
terms of his/her own value. Patients with hematologic malig-
nancies, for whom HSCT is recommended, have to deal with
the diagnosis of a threatening disease that brings feelings of
sadness and anger as well as uncertainty about the success
of the treatment. Sometimes, the problem may centre on dif-
ferent ideas about an acceptable quality of life that often
come into play in the decision-making process. The physical
and psychological burdens experienced by patients undergo-
ing HSCT are well known [80] and may have short- and
long-term quality of life (QOL) consequences, further exac-
erbating the morbidity of HSCT [81–83]. HSCT has a pro-
found and pervasive impact on the lives of survivors [84];
in a cohort of five hundred and ninety patients from six
transplant centres, Valkova et al. recently demonstrated that
patients with a GVHD had an inferior QOL score and that
QOL decreased with increasing age and increased with time
elapsed since HSCT. Despite the fact that QOL increases
steadily as more time elapses since HSCT, sometimes, the
impact of the consequences of HSCT may persist perma-
nently, thus being a substantial factor in the decision-
making process by patients [83].
In the final analysis, consent to HSCT is a complex situ-
ation-specific, value-laden, and goal-dependent process
which may best be made only after complete information
has been processed by the patient to allow a fully informed
decision. It is affected by many different factors such as the
value systems of both physician and patient, medical goals,
clinical effectiveness, sociocultural and religious context,
and the individual’s emotions and personal characteristics.
All these ethical and legal challenges are even greater
when HSCT involves the paediatric population.
The application of HSCT in the case of children and ado-
lescents is vast and growing and includes several malignant
and benign diseases which are incurable by any other thera-
pies [84, 85]. The successful treatment of many paediatric
diseases with HSCT has resulted in an increased number of
long-term survivors, thus increasing concerns about long-
term adverse effects (e.g., GVHD, opportunistic infections,
future infertility, developmental delay, and secondary malig-
nancies) [86, 87].
Paediatric patients who are also HSCT recipients gener-
ate unique concerns which are both clinical and ethical.
The basic assumption is that, in the paediatric population,
there is a tripartite relationship between the child, parents
or surrogates, and clinicians [88]. Furthermore, the paediat-
ric population includes subjects of different ages, ranging
from neonates who are completely excluded from the
decision-making process to late adolescents who are partially
able to make a decision [88]; thus, the value of involving
children and adolescents in their own medical decision
making is increasingly recognized [89].
Open communication with parents and families should
be the gold standard of the physician-parents-patient
relationship. The physician and the parents each have their
own responsibilities and concerns: those of the physician
are technical and scientific while those of the parents relate
to pain, perception, and the quality of life. Yet all cooperate
in resolving the health problems of the sick child. Parents
are active participants in a dialogue that is important in the
shared decision-making process; the physician has the bur-
den of ensuring that comprehension is achieved and that
the parents themselves are acting in the best interests of the
child. Parents, physicians, and, when possible, the paediatric
patient must consider and balance the risks of graft rejection,
infection during transplantation, immunosuppression,
GVHD, and death against the potential benefits of HSCT
when deciding about HSCT. In their studies on this issue,
authors have shown that a substantial proportion of adult
patients and parents of children with sickle cell anaemia
requiring HSCT is willing to accept a certain amount of risk
in the hopes of curing their disease and living a normal life
[90–92] with the highest levels of acceptance related to the
increased severity of the disease. However, there continue
to be significant numbers of parents and adolescents who
are unwilling to accept any risk of HSCT-associated mortal-
ity or GVHD [93].
The issue is decidedly more problematic when a mature
minor and his/her parents find themselves in disagreement
about whether or not to undergo HSCT. Mature minors,
that is, those able to understand the nature and the eventual
burdens of a medical treatment, may express strong desires
to know about their clinical condition. These can be
extremely difficult concerns for the adolescent to consider
and balance, because their decision includes the need to
consider both acute and long-term risks and benefits.
Refusal of life-sustaining medical treatment such as HSCT
may result. Whether the right to refuse life-saving therapies
applies to minors (typically defined as younger than 18,
though the definition varies according to the country) is very
complex. Generally, the legal norm for minors is that parents
provide consent on behalf of the child and the child provides
“assent” to the extent that he or she is developmentally able
to do so. The issue of the refusal of life-sustaining treatment
by mature minors is still strongly debated [94–98], and the
ability of children to refuse medical treatment is far from
certain [99].
6 Stem Cells International
Even if the right to refuse medical treatment is likely to be
restricted to those who are competent, physicians cannot just
shrug it off. Refusal of life-sustaining therapy such as HSCT
by a mature minor should be given careful consideration by
physicians and parents [88]. There are some difficult prob-
lems here that should be addressed. Physicians have the duty
to assist all the family members, including the adolescent
patient, involving other members of the multidisciplinary
team, in order to reach a shared decision consistent with their
beliefs and values. Consideration must be given to the
interests of all parties. However, respect for autonomy, self-
determination, and the best interests of the minor must
always be at the forefront. Legal advice may be helpful in
deciding whether application should be made to the court
to resolve disputes about best interests that cannot be
resolved informally. A statement from the Confederation of
European Specialists in Paediatrics clearly states that paediat-
ric patients may not refuse life-saving treatment.
Conclusively, the concerns surrounding informed con-
sent, which is one of the most challenging in HSCT, become
amplified when the subjects involved are children. The
practical understanding of children and parents of goals
and procedures, risks, future implications, and, finally, alter-
natives to HSCT is the critical key point of the informed
consent process. A balance between parental permission
and child involvement in the decision-making process
strongly depends on the age or maturity of the child and on
the degree of communication between parents and children.
Broadly, the scenario of consent to HSCT may vary from a
choice mostly based on the parent’s decision in the case of
very young children, to a joint decision as children mature,
and, finally, to a largely independent decision made by an
older adolescent with parental affirmation.
6. Conflicts of Interest
Conflict of interest has emerged as one of the most serious
ethical problems the international community faces [100].
In fact, this is an issue that affects the very dignity and
prestige of medical science as a whole but, obviously, also
the wellbeing of patients. Today, this conflict can manifest
itself in a number of specific ways [101]. Firstly, it can arise
between economic interests on the one hand and medicine
and healthcare on the other. Most biomedical research has
been predominantly carried out in and for developed coun-
tries. This is reflected in the fact that the WHO has estimated
that the vast majority of the resources devoted to research
and development on medical problems are applied to dis-
eases that affect a minority of the world population. Secondly,
it can be seen in the selection of research programmes which
are likely to give quick profit, whereas research that involves
higher costs and greater investment of time (i.e., HSCT) can
be excluded [102].
Another example of conflict of interest in HSCT is the
permission to publish research data from the sponsoring
groups which can therefore selectively choose what to pub-
lish. Finally, the need for recruiting large numbers of patients
in transplant research centres may induce physicians to pro-
pose the HSCT procedure in a convincing way to prospective
patients, rather than possible therapeutic alternatives. For
example, an important ethical issue has been the implemen-
tation of autologous HSCT in clinical practice on the basis of
phase-II trials in the 1990s and the publication of falsified
data in the first randomized controlled trials [103].
Public authorities play an active role in ensuring that
research is directed towards increasing the standards of
healthcare in the interests of people and of society and in
tempering and reconciling the pressures of different interests.
Ethical and scientific standards for carrying out biomedical
research on human subjects have been developed and
established in international guidelines [7] including the Dec-
laration of Helsinki, the CIOMS (Council for International
Organizations of Medical Sciences) International Ethical
Guidelines for Biomedical Research Involving Human Sub-
jects, and the World Health Organization and ICH (Interna-
tional Conference on Harmonization) Guidelines for Good
Clinical Practice. Compliance with guidelines helps to ensure
that the rights, safety, and dignity of research participants
and that the results of the investigations are trustworthy.
All international guidelines require ethical and scientific
review along with informed consent (and the appropriate
protection of those unable to consent) as essential measures
to protect persons who participate in research.
While the scientific review is handled by scholars, the
very purpose of an ethical committee (EC) in reviewing
biomedical research is to contribute to safeguarding the
rights, safety, and health of all actual or potential participants
in the research programme. Therefore, the people involved in
the ECs come from diverse backgrounds and are typically
lawyers, patient advocacy groups, public health experts,
professors of bioethics, an so on.
ECs should also take the principle of justice into consid-
eration so that the benefits and risks associated with a new
research programme can be fairly distributed among all
groups in society, irrespective of gender (when appropriate),
economic status, and ethnicity.
Finally, ECs should provide an independent and compe-
tent review of the ethics of proposed studies. Both in the
procedures and in decision-making, ECs need to be indepen-
dent of political and market influences.
ECs are responsible for carrying out the review of the
proposed research before it is begun, so timely evaluation is
of crucial importance. They also need to ensure that there is
a regular evaluation of the ethics of ongoing studies that
received a positive decision, as interim results can be illumi-
nating on the efficacy and side effects of new protocol.
In summary, ECs are responsible for acting in the inter-
ests of research participants, also taking into account the
interests of the researchers, and the requirements of relevant
regulatory agencies and all applicable laws.
7. Conclusions
When discussing ethical and legal issues in HSCT, there are
many controversial areas. This paper offers a brief descrip-
tion of some questions, but it is neither complete nor
comprehensive. Hopefully, it may serve to stimulate the
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discussion of such themes within the medical community,
involving also the society at large.
As HSCT practices increase, the challenges are great.
Some of the ethical issues will be worked out in the privacy
of the physician-patient relationship. Medical indications
for HSCT, the likely success of HSCT, the patient’s
preferences and expectations, his/her quality of life, and the
patient’s contextual features are the core of the decision-
making process, representing the real relevant facts pertain-
ing to the situation into account. All these issues are
decidedly more problematic when they concern a patient
who is a minor. At the same time, however, the concern of
physicians should be for the good of society and the financial
sustainability of the healthcare system, thus extending
benefits as equitably as possible.
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